Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1969 2
1970 1
1971 5
1972 5
1973 4
1974 1
1975 12
1976 2
1977 10
1978 5
1979 6
1980 7
1981 7
1982 7
1983 8
1984 10
1985 14
1986 3
1987 8
1988 12
1989 14
1990 19
1991 19
1992 10
1993 14
1994 30
1995 22
1996 28
1997 33
1998 44
1999 51
2000 61
2001 47
2002 67
2003 48
2004 59
2005 61
2006 79
2007 67
2008 84
2009 93
2010 96
2011 78
2012 100
2013 125
2014 143
2015 138
2016 136
2017 142
2018 136
2019 147
2020 165
2021 174
2022 181
2023 186
2024 80

Text availability

Article attribute

Article type

Publication date

Search Results

2,757 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Recurrent Thyroid Gland Carcinoma"
Page 1
Molecular basis and targeted therapy in thyroid cancer: Progress and opportunities.
Zhang L, Feng Q, Wang J, Tan Z, Li Q, Ge M. Zhang L, et al. Biochim Biophys Acta Rev Cancer. 2023 Jul;1878(4):188928. doi: 10.1016/j.bbcan.2023.188928. Epub 2023 May 29. Biochim Biophys Acta Rev Cancer. 2023. PMID: 37257629 Free article. Review.
Thyroid cancer (TC) is the most prevalent endocrine malignant tumor. Surgery, chemotherapy, radiotherapy, and radioactive iodine (RAI) therapy are the standard TC treatment modalities. However, recurrence or tumor metastasis remains the main challenge in the managem …
Thyroid cancer (TC) is the most prevalent endocrine malignant tumor. Surgery, chemotherapy, radiotherapy, and radioactive iodine (RAI …
Radioactive Iodine Therapy in Differentiated Thyroid Cancer: 2020 Update.
Ciarallo A, Rivera J. Ciarallo A, et al. AJR Am J Roentgenol. 2020 Aug;215(2):285-291. doi: 10.2214/AJR.19.22626. Epub 2020 Jun 17. AJR Am J Roentgenol. 2020. PMID: 32551904 Review.
This principle is being applied to radioactive iodine therapy. Consequently, thyroid cancer therapy protocols are evolving. The purpose of this article is to promote a modern approach to radioiodine therapy. ...This article highlights guidelines and position statements, su …
This principle is being applied to radioactive iodine therapy. Consequently, thyroid cancer therapy protocols are evolving. The purpo …
Current practice in patients with differentiated thyroid cancer.
Schlumberger M, Leboulleux S. Schlumberger M, et al. Nat Rev Endocrinol. 2021 Mar;17(3):176-188. doi: 10.1038/s41574-020-00448-z. Epub 2020 Dec 18. Nat Rev Endocrinol. 2021. PMID: 33339988 Review.
By contrast, patients with high-risk DTC represent 5-10% of all patients. Most thyroid cancer-related deaths occur in this group of patients and recurrences are frequent. ...Prospective trials are needed in well-selected patients with DTC to demonstrate the extent t …
By contrast, patients with high-risk DTC represent 5-10% of all patients. Most thyroid cancer-related deaths occur in this group of p …
Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer.
American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer; Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Pacini F, Schlumberger M, Sherman SI, Steward DL, Tuttle RM. American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, et al. Thyroid. 2009 Nov;19(11):1167-214. doi: 10.1089/thy.2009.0110. Thyroid. 2009. PMID: 19860577 Free article.
BACKGROUND: Thyroid nodules are a common clinical problem, and differentiated thyroid cancer is becoming increasingly prevalent. ...CONCLUSIONS: We created evidence-based recommendations in response to our appointment as an independent task force by the Ameri …
BACKGROUND: Thyroid nodules are a common clinical problem, and differentiated thyroid cancer is becoming increasingly p …
Follicular cell-derived thyroid cancer.
Dralle H, Machens A, Basa J, Fatourechi V, Franceschi S, Hay ID, Nikiforov YE, Pacini F, Pasieka JL, Sherman SI. Dralle H, et al. Nat Rev Dis Primers. 2015 Dec 10;1:15077. doi: 10.1038/nrdp.2015.77. Nat Rev Dis Primers. 2015. PMID: 27188261 Review.
Follicular cell-derived thyroid cancers are derived from the follicular cells in the thyroid gland, which secrete the iodine-containing thyroid hormones. ...In thyroid cancer surgery, for instance, injuries to structures outside the thyroid …
Follicular cell-derived thyroid cancers are derived from the follicular cells in the thyroid gland, which secrete the i …
Controversial Issues in Thyroid Cancer Management.
Tuttle RM. Tuttle RM. J Nucl Med. 2018 Aug;59(8):1187-1194. doi: 10.2967/jnumed.117.192559. Epub 2018 Apr 13. J Nucl Med. 2018. PMID: 29653980 Free PMC article. Review.
The lack of prospective randomized clinical trials for most management topics in differentiated thyroid cancer forces us to make management recommendations based on retrospective observational data, which are often incomplete, subject to selection bias, and c …
The lack of prospective randomized clinical trials for most management topics in differentiated thyroid cancer forces u …
Surgical management of medullary thyroid carcinoma.
Konstantinidis A, Stang M, Roman SA, Sosa JA. Konstantinidis A, et al. Updates Surg. 2017 Jun;69(2):151-160. doi: 10.1007/s13304-017-0443-y. Epub 2017 Apr 13. Updates Surg. 2017. PMID: 28409442 Review.
Medullary thyroid cancer (MTC) is a malignant tumor of the parafollicular C cells of the thyroid and comprises only 1-2% of all thyroid cancer cases. Unlike most differentiated thyroid cancer, MTC is associated with a mean survival of 8.6 years and acc …
Medullary thyroid cancer (MTC) is a malignant tumor of the parafollicular C cells of the thyroid and comprises only 1-2% of al …
Lenvatinib: first global approval.
Scott LJ. Scott LJ. Drugs. 2015 Apr;75(5):553-60. doi: 10.1007/s40265-015-0383-0. Drugs. 2015. PMID: 25795101 Review.
Ltd for the treatment of solid tumours, primarily for differentiated thyroid cancer, and other malignancies. A capsule formulation of the drug has received approval in the USA for use in locally recurrent or metastatic, progressive, radioactive iodine-refractory dif …
Ltd for the treatment of solid tumours, primarily for differentiated thyroid cancer, and other malignancies. A capsule formulation of …
The Treatment of Thyroid Cancer With Radiofrequency Ablation.
Pace-Asciak P, Russell JO, Tufano RP. Pace-Asciak P, et al. Tech Vasc Interv Radiol. 2022 Jun;25(2):100825. doi: 10.1016/j.tvir.2022.100825. Epub 2022 Mar 10. Tech Vasc Interv Radiol. 2022. PMID: 35551804 Free article. Review.
In the past decade, there has seen been a shift from treating all thyroid cancer surgically, to favoring less aggressive approaches for low-risk thyroid cancer. ...Thermal ablation has developed as a minimally invasive alternative to surgery and active surveillance …
In the past decade, there has seen been a shift from treating all thyroid cancer surgically, to favoring less aggressive approaches f …
Thyroid gland invasion in total laryngectomy: A systematic review and meta-analysis.
Xie J, Wu P, Liu H, Zhang S, Lu Z. Xie J, et al. Int J Surg. 2022 Mar;99:106262. doi: 10.1016/j.ijsu.2022.106262. Epub 2022 Feb 13. Int J Surg. 2022. PMID: 35172203 Free article. Review.
Subglottic tumors (odds ratio [OR], 3.74; 95% CI, 1.75-7.99), T4 stage tumors (OR, 2.39; 95% CI, 1.20-4.75), subglottic extension (OR, 3.85; 95% CI,2.09-7.11), and thyroid cartilage invasion (OR, 3.98; 95% CI, 1.47-10.75) are risk factors for thyroid invasion, and n …
Subglottic tumors (odds ratio [OR], 3.74; 95% CI, 1.75-7.99), T4 stage tumors (OR, 2.39; 95% CI, 1.20-4.75), subglottic extension (OR, 3.85; …
2,757 results